Axsome Therapeutics Inc
AXSM
Get informed when a big investor buys or sells
+ FollowMarket Cap$12.03B
Close$
$23.38
90.1% downside
Current Fair Value
90.1% downsideOvervalued by 90.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $12.03 Billion |
|---|---|
| Enterprise Value | $11.94 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.68 |
| Beta | 0.6 |
| Outstanding Shares | 51,198,349 |
Return
| Return on Equity | -344.96% |
|---|---|
| Return on Assets | -26.39% |
| Return on Invested Capital | -58.29% |
Valuation & Multiples
| P/E Ratio | -62.68 |
|---|---|
| PEG | -726.08 |
| Price to Sales | 18.1 |
| Price to Book Ratio | 235.26 |
| Enterprise Value to Revenue | 16.86 |
| Enterprise Value to EBIT | -74.67 |
| Enterprise Value to Net Income | -64 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 3.97 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 11, 2026
EPS Estimate
$-0.79
Average shareholder expectationRevenue Estimate
$195.13 M
Average shareholder expectationNext Earnings Call
Expected Date
August 3, 2026
EPS Estimate
$-0.86
Average shareholder expectationRevenue Estimate
$221.62 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 93.90% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.02%▼ 75.19% |
|---|---|
| Total Invested | $127.77M▼ 98.01% |
| Investors Holding | 13▼ 417.00% |
ESG Score
No data
About Axsome Therapeutics Inc
CEO: Herriot Tabuteau Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people facing unsatisfactory tre...